Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangxue Anshen Pian is a traditional Chinese medicine (TCM) oral tablet developed and manufactured by Beijing Yushengtang Pharmaceutical. It is formulated to nourish the blood, tonify the liver and kidney, and calm the nerves (An Shen). The formula typically consists of several herbal ingredients, including *Spatholobus suberectus* (Ji Xue Teng), *Rehmannia glutinosa* (Shu Di Huang), *Polygonum multiflorum* (He Shou Wu), *Eclipta prostrata* (Mo Han Lian), *Ligustrum lucidum* (Nu Zhen Zi), and *Albizia julibrissin* (He Huan Pi). It is primarily indicated for the treatment of insomnia, palpitations, dizziness, and restlessness associated with blood deficiency and liver-kidney yin deficiency. As an approved TCM product in China, it is widely used for its sedative and mood-stabilizing properties without the typical side effects of synthetic hypnotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yangxue Anshen Pian.